top_image

Management Team

Peng Liang, Ph.D.

Co-Founder, President, Chairman
 




  • Founder & CEO of GenHunter Corporation
  • Inventor of Trimer-Tag© technology
  • Co-inventor of Differential Display technology
  • Discovered IL-24 and its receptors (licensed to Wyeth)
  • Winner of 1998 Molecular Bioanalytics Prize from the German Society of Biological Chemistry & Molecular Biology
  • Published 75+ original research papers in peer-reviewed journals
  • Former Associate Professor of Cancer Biology, Vanderbilt University
  • Postdoc, Harvard Medical School under Dr. Arthur Pardee
  • PhD in Biochemistry, University of Illinois
  • BS in Biology, Beijing University


Joshua Liang

Chief Strategy Officer, Board Director




  • Oversee company operations & strategy; since joining Clover in 2016, raised over RMB 400 million (~US$60 million) in total capital, tripled FTE headcount to nearly 100 by early 2019, initiated Clover's first clinical trials in Australia & China and led immuno-oncology R&D programs 
  • Former investment banker at Centerview Partners in the healthcare advisory practice, primarily focused in the life sciences sector
-Worked on over US$20bn of announced biopharma mergers & acquisitions
-Advised leading biopharmaceutical companies on corporate strategy, business development and financing needs
  • Previous experience at UBS Investment Bank, Vertex Pharmaceuticals and ICBC International
  • BS in Economics, The Wharton School
  • BA in Biology, University of Pennsylvania
  • Roy & Diana Vagelos Program in Life Sciences & Management


Min Dong, Ph.D.

EVP, Global Clinical Development
 



 
 
  • Previously SVP, Clinical Development at EOC Pharma
  • 10 years at Novartis (Shanghai & Basel), serving as Director of Global Program Team in the Oncology Translational Medicine unit
  • PhD in Molecular & Systems Toxicology and Pharmacology, MIT
  • M.S. in Molecular Biophysics, Tsinghua University


Zheng Ping   

Director, Operations & Board Director



  • Former CEO of Hui Cheng Pharmaceuticals, where he oversaw launches of several small molecule drugs
  • Former VP, Sichuan Industrial Institute of Antibiotics
  • BS in Biology, Sichuan University


Scientific Advisory Board


Xiaodong Wang, Ph.D. 

Founding Advisor, Board Director
 
 


  • Founder of BeiGene (Nasdaq: BGNE) since 2010, and Chairman of Scientific Advisory Board since 2011
  • Founding Director & Architect of 700-person team at the National Institute of Biological Sciences (NIBS) in Beijing (2003-present)
  • Howard Hughes Medical Institute Investigator, George L. MacGregor Distinguished Chair in Biomedical Sciences (1997-2010) and Professor in Biomedical Sciences (2001-2010) at University of Texas Southwestern Medical Center
  • Member of National Academy of Sciences, USA
  • Foreign associate of Chinese Academy of Sciences
  • Founder of Joyant Pharmaceuticals, venture capital-backed oncology biotech in US
  • PhD in Biochemistry from University of Texas Southwestern Medical Center
  • BS in Biology from Beijing Normal University



Jianwei Zhu, Ph.D., MBA

Founding Advisor, Board Director
 
 


  • President & CEO, Jecho Biopharmaceuticals
  • Director of Biopharma Development Program, SAIC-Frederick
  • Dean, School of Pharmacy, Shanghai Jiao Tong University
  • Consultant to International Vaccine Institute, US NIH, Boehringer Ingelheim, Talecris, Cytogenix
  • MBA, Hood Business School
  • Postdoc, MIT & Harvard Medical School
 

Jinyou Zhang, Ph.D.

Scientific Advisory Board – Biomanufacturing
 




  • Head of Bioprocess Development & Manufacturing, BeiGene
  • Over 24 years of industry experience in bioprocessing and biomanufacturing
  • Well-established in developing culture media and upstream processes
  • Published 40 original research papers in peer-reviewed journals (lead author on 24)
  • Former Vice President and Site Head of Biomanufacturing at WuXi AppTec
  • Vice President of Process Development and Manufacturing at Immunomedics in Morris Plains, NJ
  • Executive Director of Bioprocess R&D at Novavax
  • Senior Investigator with 15 years development experience at Bioprocess R&D, Merck
  • PhD in Biochemical Engineering from Massachusetts Institute of Technology in 1991 under supervision of Professor Arnold Demain (Fellow of U.S. Academy of Science, Ex-President of Society of Industrial Microbiology)



Shun Luo, Ph.D.

Scientific Advisory Board – Process Development
 




  • President, Jianshun Biosciences
  • Former Scientific Director in Cell Science & Process Development, Amgen
  • Former Media Group Leader, Genentech
  • Former R&D Head, JRH Biosciences
  • Former Research Scientist, Ares Serono
  • Postdoc, Harvard Medical School
  • PhD in Microbiology & Immunology, Virginia Tech
 

 

Karl Zhou, Ph.D.
Scientific Advisory Board – Clinical Development
 





  • 20+ years of clinical development experience at global leading pharmaceutical and CRO companies, with a focus on oncology drugs
  • Oversaw early and late stage clinical development of world's first approved immuno-oncology antibody Yervoy (ipilimumab) targeting CTLA-4
  • Previously served as Senior Medical Director and Clinical Lead at inVentiv Health, AstraZeneca, Pfizer, Baxter International and Schering-Plough
  • Clinical Fellowship, Dana-Farber Cancer Institute
  • Postdoc, Harvard Medical School under Dr. Emil Frei III
  • PhD, Baylor College of Medicine